Also trades as: ITRMF (OTC) · $vol 0M
ITRM NASDAQ
Iterum Therapeutics plc
1W: -6.4%
1M: -79.9%
3M: -89.3%
YTD: -89.3%
1Y: -97.2%
3Y: -96.5%
5Y: -99.8%
$0.03
Last traded 2026-04-06 — delisted
Overview
Chart
Smart Money
Financials
Income Statement
Cash Flow
Balance Sheet
Earnings
Analysis
Technicals
Weather
Peers
ESG
Institutions
Dark Pool
Short Interest
Supply Chain
Income Trends
Revenue
$0
+0.0% ▲
Gross Profit
-$254K
+85.5% ▲
Operating Income
-$19M
+60.6% ▲
Net Income
-$25M
+35.4% ▲
EPS (Diluted)
$-1.26
+57.4% ▲
EBITDA
-$22M
+37.2% ▲
Profit Margins
Year-over-Year Growth
View Full Income Statement
| Line Item | FY2020 | FY2021 | FY2022 | FY2023 | FY2024 |
|---|---|---|---|---|---|
| Revenue | $0 | $0 | $0 | $0 | $0 |
| YoY Growth | -100.0% | +0.0% | +0.0% | +0.0% | +0.0% |
| Cost of Revenue | $161K | $2M | $2M | $2M | $254K |
| Gross Profit | -$161K | -$2M | -$2M | -$2M | -$254K |
| Gross Margin | — | — | — | — | — |
| R&D Expenses | $21M | $9M | $16M | $38M | $10M |
| SG&A Expenses | $11M | $14M | $13M | $7M | $8M |
| Operating Expenses | $32M | $22M | $29M | $46M | $18M |
| Operating Income | -$32M | -$25M | -$30M | -$47M | -$19M |
| Operating Margin | — | — | — | — | — |
| Interest Expense | $15M | $6M | $2M | $0 | $0 |
| Income Before Tax | -$51M | -$91M | -$44M | -$38M | -$25M |
| Tax Expense | $743K | $705K | $301K | $613K | $240K |
| Net Income | -$52M | -$92M | -$44M | -$38M | -$25M |
| Net Margin | — | — | — | — | — |
| EPS (Diluted) | $-32.49 | $-8.41 | $-3.63 | $-2.96 | $-1.26 |
| EBITDA | -$36M | -$83M | -$40M | -$35M | -$22M |
| Shares Outstanding | 24M | 11M | 12M | 13M | 20M |